SUMO-Specific Protease 1 (SENP1) Reverses the Hormone-Augmented SUMOylation of Androgen Receptor and Modulates Gene Responses in Prostate Cancer Cells
Open accessThe DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
The acceptor sites for small ubiquitin-like modifier (SUMO) are conserved in the N-terminal domains of several nuclear receptors. Here, we show that androgens induce rapid and dynamic conjugation of SUMO-1 to androgen receptor (AR). Nuclear import of AR is not sufficient for SUMOylation, because constitutively nuclear apo-ARs or antagonist-bound ARs are only very weakly modified by SUMO-1 in comparison with agonist-bound ARs. Of the SUMO-specific proteases (SENP)-1, -2, -3, -5, and -6, only SENP1 and SENP2 are efficient in cleaving AR-SUMO-1 conjugates in intact cells and in vitro. Both SENP1 and -2 are nuclear and found at sites proximal to AR. Their expression promotes AR-dependent transcription, but in a promoter-selective fashion. SENP1 and -2 stimulated the activity of holo-AR on compound androgen response element-containing promoters. The effects of SENP1 and -2 on AR-dependent transcription were dependent on catalytic activity and required intact SUMO acceptor sites in AR, indicating that their coactivating effects are mainly due to their direct isopeptidase activity on holo-AR. In prostate cancer cells, ectopic expression of SENP1, but not that of SENP2, increased the transcription activity of endogenous AR. Silencing of SENP1 attenuated the expression of several AR target genes and blunted androgen-stimulated growth of LNCaP cells. Our results indicate that SENP1 reverses the ligand-induced SUMOylation of AR and helps fine tune the cellular responses to androgens in a target promoter-selective manner.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Proteasome-Independent Functions of Ubiquitin in Endocytosis and Signaling
Mukhopadhyay, D., & Riezman, H. (2007) · Science · doi:10.1126/science.1127085 · Cited by 1,221
Scher, H. I., & Sawyers, C. L. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.4777 · Cited by 1,025 · cited 5×
“Mol Endocrinol, March 2009, 23(3):292–307 mend.”
InfluentialHeemers, H. V., & Tindall, D. J. (2007) · Endocrine Reviews · doi:10.1210/er.2007-0019 · Cited by 753
Transcriptional activation and nuclear targeting signals of the human androgen receptor.
Simental, J. A., Sar, M., Lane, M. V., French, F. S., & Wilson, E. M. (1991) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)52466-2 · Cited by 631
Ghisletti, S., Huang, W., Ogawa, S., Pascual, G., Lin, M.-E., Willson, T. M., Rosenfeld, M. G., & Glass, C. K. (2007) · Molecular Cell · doi:10.1016/j.molcel.2006.11.022 · Cited by 561 · cited 1×
“In contrast to GR and AR, SUMO-2 and -3 are preferentially conjugated to ligand-bound liver X receptor- (37), with HDAC4 enhancing the conjugations in a SUMO E3 ligase-like fashion.”
Direct, Androgen Receptor-Mediated Regulation of the FKBP5 Gene via a Distal Enhancer Element
Magee, J. A., Chang, L.-W., Stormo, G. D., & Milbrandt, J. (2006) · Endocrinology · doi:10.1210/en.2005-1001 · Cited by 174
Potentiation of glucocorticoid receptor transcriptional activity by sumoylation
Le Drean, Y., Mincheneau, N., Le Goff, P., & Michel, D. (2002) · Endocrinology · doi:10.1210/en.2002-220135 · Cited by 159
Haelens, A., Tanner, T., Denayer, S., Callewaert, L., & Claessens, F. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-1701 · Cited by 153
Kraus, S., Gioeli, D., Vomastek, T., Gordon, V., & Weber, M. J. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0596 · Cited by 118
Self-citationYang, C.-S., Xin, H.-W., Kelley, J. B., Spencer, A., Brautigan, D. L., & Paschal, B. M. (2007) · Molecular and Cellular Biology · doi:10.1128/mcb.02411-06 · Cited by 55 · cited 1×
“Flag-AR5A is a compound mutant in which S81, S94, S256, S308, and S424 are all converted to alanines (80).”
Self-citationKesler, C. T., Gioeli, D., Conaway, M. R., Weber, M. J., & Paschal, B. M. (2007) · Molecular Endocrinology · doi:10.1210/me.2007-0240 · Cited by 35 · cited 2×
“The AR-NLS displays androgen-independent nuclear localization, whereas the AR-NES is predominantly cytoplasmic even in the presence of androgen (39).”
Self-citation
Cited by
Partners in crime: deregulation of AR activity and androgen synthesis in prostate cancer
Knudsen, K. E., & Penning, T. M. (2010) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2010.01.002 · Cited by 293
Post-Translational Modifications of Nuclear Receptors and Human Disease
Anbalagan, M., Huderson, B., Murphy, L., & Rowan, B. G. (2012) · Nuclear Receptor Signaling · doi:10.1621/nrs.10001 · Cited by 211
“…of SENP1 attenuated the expression of several AR target genes and inhibited the androgen-stimulated growth of LNCaP cells (androgen-dependent prostate cancer cells) www.nursa.org NRS | 2012 | Vol. 10 | DOI: 10.1621/nrs.10001 | Page 2 of 13 [Bawa-Khalfe et al., 2007; Kaikkonen et al., 2009].”
InfluentialNuclear receptor coactivators: structural and functional biochemistry
Bulynko, Y. A., & O’Malley, B. W. (2011) · Biochemistry · doi:10.1021/bi101762x · Cited by 113
“The recently described desumoylation of AR and PR by SENP-1 (59, 60) highlights this enzyme as an important coactivator that opposes inhibitory PTMs on these NRs.”
BackgroundInhibition of androgen receptor activity by histone deacetylase 4 through receptor SUMOylation
Yang, Y., Tse, A. K.-W., Li, P., Ma, Q., Xiang, S., Nicosia, S. V., Seto, E., Zhang, X., & Bai, W. (2011) · Oncogene · doi:10.1038/onc.2010.600 · Cited by 72
RAS GTPases are modified by SUMOylation
Choi, B. H., Chen, C., Philips, M., & Dai, W. (2018) · Oncotarget · doi:10.18632/oncotarget.23269 · Cited by 32
Metadata
- Authors
- Kaikkonen, S., Jääskeläinen, T., Karvonen, U., Rytinki, M. M., Makkonen, H., Gioeli, D., Paschal, B. M., & Palvimo, J. J.
- Venue
- Molecular Endocrinology
- Publisher
- The Endocrine Society
- Published
- 2009-03-01
- Volume
- 23
- Issue
- 3
- Pages
- 292-307
- ISSN
- 0888-8809 (ISSN-L)
- 1944-9917
- OpenAlex
- W2169521652
- Cited by
- 115
- References
- 11
- FWCI
- 5.29
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.